PriceTargets.com logo

LifeStance Health Group - LFST Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.83
  • Forecasted Upside: 43.40%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.16 As of 04/25/2024 05:00 PM ET
▼ -0.01 (-0.16%)

This chart shows the closing price for LFST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LifeStance Health Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LFST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LFST

Analyst Price Target is $8.83
▲ +43.40% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for LifeStance Health Group in the last 3 months. The average price target is $8.83, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 43.40% upside from the last price of $6.16.

This chart shows the closing price for LFST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in LifeStance Health Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00Low
3/6/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$8.00 ➝ $9.00Low
3/4/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $9.00Low
2/29/2024BarclaysBoost TargetUnderweight ➝ Underweight$7.00 ➝ $8.00Low
1/3/2024BarclaysInitiated CoverageUnderweight$7.00Low
11/22/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00Low
11/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$10.00 ➝ $8.00Low
8/10/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00Low
5/15/2023TD CowenDowngradeOutperform ➝ Market Perform$8.00 ➝ $9.00Low
1/6/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$8.00Low
11/15/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $8.00Low
11/14/2022CowenLower TargetOutperform$10.00 ➝ $8.00Low
11/14/2022CowenLower TargetOutperform$10.00 ➝ $8.00Low
11/7/2022Jefferies Financial GroupReiterated RatingBuy$7.25Low
8/22/2022CowenLower TargetOutperform$11.00 ➝ $10.00Low
8/22/2022CowenLower Target$11.00 ➝ $10.00Low
3/21/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $10.00High
3/17/2022UBS GroupDowngradeBuy ➝ Neutral$19.00 ➝ $10.00High
12/17/2021Morgan StanleyLower TargetEqual Weight$15.00 ➝ $10.00High
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $12.00High
9/9/2021CowenInitiated CoverageOutperform$18.00High
8/16/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$36.00 ➝ $16.00Medium
7/6/2021UBS GroupInitiated CoverageBuy$34.00Medium
7/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$36.00Medium
7/6/2021William BlairInitiated CoverageOutperformMedium
7/6/2021Morgan StanleyInitiated CoverageOverweight$36.00Medium
7/5/2021The Goldman Sachs GroupInitiated CoverageNeutral$25.00Medium
7/5/2021Jefferies Financial GroupInitiated CoverageBuy$36.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 11 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

LifeStance Health Group logo
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Read More

Today's Range

Now: $6.16
Low: $6.01
High: $6.17

50 Day Range

MA: $6.46
Low: $5.62
High: $8.71

52 Week Range

Now: $6.16
Low: $4.74
High: $9.59

Volume

864,655 shs

Average Volume

1,309,385 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of LifeStance Health Group?

The following sell-side analysts have issued reports on LifeStance Health Group in the last twelve months: Barclays PLC, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, TD Cowen, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for LFST.

What is the current price target for LifeStance Health Group?

6 Wall Street analysts have set twelve-month price targets for LifeStance Health Group in the last year. Their average twelve-month price target is $8.83, suggesting a possible upside of 44.8%. Morgan Stanley has the highest price target set, predicting LFST will reach $10.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $8.00 for LifeStance Health Group in the next year.
View the latest price targets for LFST.

What is the current consensus analyst rating for LifeStance Health Group?

LifeStance Health Group currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LFST, but not buy more shares or sell existing shares.
View the latest ratings for LFST.

What other companies compete with LifeStance Health Group?

Other companies that are similar to LifeStance Health Group include Apollo Medical, Privia Health Group, Magellan Health, U.S. Physical Therapy and Progyny. Learn More about companies similar to LifeStance Health Group.

How do I contact LifeStance Health Group's investor relations team?

The company's listed phone number is 602-767-2100 and its investor relations email address is [email protected]. The official website for LifeStance Health Group is www.lifestance.com. Learn More about contacing LifeStance Health Group investor relations.